MTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and Treatment

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 May 8

PMID 24804240

Citations 18

Authors

Zhuo Wang

Wei Jin

Hongchuan Jin

Xian Wang

Affiliations

Soon will be listed here.

Abstract

As the fifth most common cancer in men and the eighth most common cancer in women, hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide, with standard chemotherapy and radiation being minimally effective in prolonging survival. Virus hepatitis, particularly HBV and HCV infection is the most prominent risk factor for HCC development. Mammalian target of rapamycin (mTOR) pathway is activated in viral hepatitis and HCC. mTOR inhibitors have been tested successfully in clinical trials for their antineoplastic potency and well tolerability. Treatment with mTOR inhibitor alone or in combination with cytotoxic drugs or targeted therapy drug scan significantly reduces HCC growth and improves clinical outcome, indicating that mTOR inhibition is a promising strategy for the clinical management of HCC.

Citing Articles

Metformin in Antiviral Therapy: Evidence and Perspectives.

Halabitska I, Petakh P, Lushchak O, Kamyshna I, Oksenych V, Kamyshnyi O Viruses. 2025; 16(12.

PMID: 39772244 PMC: 11680154. DOI: 10.3390/v16121938.

HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.

Pascut D, Hoang M, Nguyen N, Pratama M, Tiribelli C Cancers (Basel). 2021; 13(10).

PMID: 34069740 PMC: 8161081. DOI: 10.3390/cancers13102485.

Chang S, Tsai C, Liu K, Wang S, Hsu J, Yeh T Front Endocrinol (Lausanne). 2021; 12:639967.

PMID: 33868173 PMC: 8047461. DOI: 10.3389/fendo.2021.639967.

Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal" liver tissues.

Bortolami M, Comparato A, Benna C, Errico A, Maretto I, Pucciarelli S PLoS One. 2020; 15(12):e0244356.

PMID: 33362215 PMC: 7757890. DOI: 10.1371/journal.pone.0244356.

Growth and Metabolic Response of Chinese Perch to Different Dietary Protein-to-Energy Ratios in Artificial Diets.

Alam M, Liang X, Liu L, He S, Kuang Y, Hoseinifar S Int J Mol Sci. 2019; 20(23).

PMID: 31795078 PMC: 6928951. DOI: 10.3390/ijms20235983.

References

Gedaly R, Angulo P, Hundley J, Daily M, Chen C, Koch A . PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res. 2010; 30(12):4951-8. PMC: 3141822. View

Piguet A, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C . Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol. 2008; 49(1):78-87. DOI: 10.1016/j.jhep.2008.03.024. View

Chaneton B, Gottlieb E . Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci. 2012; 37(8):309-16. DOI: 10.1016/j.tibs.2012.04.003. View

Land S, Tee A . Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007; 282(28):20534-43. DOI: 10.1074/jbc.M611782200. View

Shrivastava S, Bhanja Chowdhury J, Steele R, Ray R, Ray R . Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling. J Virol. 2012; 86(16):8705-12. PMC: 3421755. DOI: 10.1128/JVI.00616-12. View

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C . Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. BMC Cancer. 2012; 12:166. PMC: 3469344. DOI: 10.1186/1471-2407-12-166. View

Shiah H, Chen C, Dai C, Hsiao C, Lin Y, Su W . Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2012; 37(1):62-73. DOI: 10.1111/apt.12132. View

Wang H, Wu H, Chen C, Fausto N, Lei H, Su I . Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol. 2003; 163(6):2441-9. PMC: 1892360. DOI: 10.1016/S0002-9440(10)63599-7. View

Altmeyer A, Josset E, Denis J, Gueulette J, Slabbert J, Mutter D . The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy. Int J Oncol. 2012; 41(4):1381-6. DOI: 10.3892/ijo.2012.1583. View

10.

Wang W, London W, Feitelson M . Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res. 1991; 51(18):4971-7. View

11.

Kim E, Goraksha-Hicks P, Li L, Neufeld T, Guan K . Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol. 2008; 10(8):935-45. PMC: 2711503. DOI: 10.1038/ncb1753. View

12.

Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A . Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003; 112(12):1809-20. PMC: 297002. DOI: 10.1172/JCI20039. View

13.

VanderWeele D, Zhou R, Rudin C . Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther. 2005; 3(12):1605-13. View

14.

Sengupta S, Peterson T, Sabatini D . Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010; 40(2):310-22. PMC: 2993060. DOI: 10.1016/j.molcel.2010.09.026. View

15.

Villanueva A, Chiang D, Newell P, Peix J, Thung S, Alsinet C . Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008; 135(6):1972-83, 1983.e1-11. PMC: 2678688. DOI: 10.1053/j.gastro.2008.08.008. View

16.

Yen C, Lin Y, Yen C, Tsai H, Tsai T, Chang K . Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One. 2012; 7(7):e41931. PMC: 3407061. DOI: 10.1371/journal.pone.0041931. View

17.

Thomas H, Mercer C, Carnevalli L, Park J, Andersen J, Conner E . mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med. 2012; 4(139):139ra84. PMC: 3703151. DOI: 10.1126/scitranslmed.3003923. View

18.

Haar E, Lee S, Bandhakavi S, Griffin T, Kim D . Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007; 9(3):316-23. DOI: 10.1038/ncb1547. View

19.

Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. PMC: 4208619. DOI: 10.1056/NEJMoa1009290. View

20.

Vinciguerra M, Veyrat-Durebex C, Moukil M, Rubbia-Brandt L, Rohner-Jeanrenaud F, Foti M . PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology. 2008; 134(1):268-80. DOI: 10.1053/j.gastro.2007.10.010. View